Rheumatology Unit, ERN ReCONNET Center, Meyer Children's Hospital IRCCS, 50139 Firenze, Italy.
Neurofarba Department, University of Florence, 50141 Firenze, Italy.
Medicina (Kaunas). 2023 Nov 17;59(11):2027. doi: 10.3390/medicina59112027.
This narrative review aims to report the main clinical manifestations, therapeutic strategies, outcomes, and complications of acute SARS-CoV-2 infection in childhood and to summarize the data relating the SARS-CoV-2 vaccination efficacy and safety in pediatric age. SARS-CoV-2 infection mostly occurs asymptomatically in the pediatric population, while multisystem inflammatory syndrome in children (MIS-C) represents the most severe coronavirus disease 2019 (COVID-19)-related illness, a life-threatening event with a high morbidity rate. After the development of SARS-CoV-2 vaccines and their subsequent approval in children, the rate of infection as well as the number of its related complications have shown a drastic decrease. Fully vaccinated children are protected from the risk of developing a severe disease and a similar protective role has been observed in the reduction of complications, in particular MIS-C. However, long-lasting immunity has not been demonstrated, booster doses have been required, and reinfection has been observed. With regards to vaccine safety, adverse events were generally mild to moderate in all age groups: local adverse events were the most commonly reported. Nevertheless, a potential association between SARS-CoV-2 vaccine and the subsequent development of inflammatory manifestations has been suggested. Myocarditis has rarely been observed following vaccination; it appeared to be more frequent among adolescent males with a mild clinical course leading to a complete recovery. SARS-CoV-2 vaccine-related MIS-C cases have been described, although a univocal definition and an exact time interval with respect to vaccination has not been reported, thus not establishing a direct causal link. Current evidence about COVID-19 vaccination in children and adolescents suggest that benefits outweigh potential risks. Long-term data collection of the post-authorization safety surveillance programs will better define the real incidence of SARS-CoV-2 vaccine-related complications in the pediatric population.
这篇叙述性综述旨在报告儿童急性 SARS-CoV-2 感染的主要临床表现、治疗策略、结局和并发症,并总结与 SARS-CoV-2 疫苗在儿科人群中的疗效和安全性相关的数据。SARS-CoV-2 感染在儿科人群中大多无症状,而儿童多系统炎症综合征(MIS-C)是最严重的 2019 年冠状病毒病(COVID-19)相关疾病,是一种发病率高的危及生命的事件。SARS-CoV-2 疫苗开发及其在儿童中的后续批准后,感染率及其相关并发症的数量均大幅下降。完全接种疫苗的儿童可免受发生重症疾病的风险,且在减少并发症方面也观察到类似的保护作用,特别是 MIS-C。然而,尚未证明其具有持久免疫力,需要加强剂量,并且已经观察到再感染。关于疫苗安全性,所有年龄段的不良事件通常为轻度至中度:局部不良事件是最常见的报告类型。然而,已经提出了 SARS-CoV-2 疫苗与随后发生炎症表现之间存在潜在关联的假设。心肌炎在接种疫苗后很少观察到;它似乎在有轻度临床病程导致完全恢复的青少年男性中更为常见。已经描述了与 SARS-CoV-2 疫苗相关的 MIS-C 病例,但尚未报告明确的定义和确切的接种时间间隔,因此未建立直接的因果关系。关于儿童和青少年 COVID-19 疫苗接种的当前证据表明,益处超过潜在风险。授权后安全性监测计划的长期数据收集将更好地确定 SARS-CoV-2 疫苗在儿科人群中相关并发症的真实发生率。